The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Research Should Focus on Particular Groups of Patients

Rheumatology Drug Research Should Focus on Particular Groups of Patients

July 1, 2013 • By Deborah Levenson

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Understanding the characteristics of intended treatment populations that are of most interest to payers can aid in strategic drug product development and commercial planning, he added. Researchers should look at patient populations and determine who is undertreated or unresponsive to treatment, expensive to treat, adherent or not, and at high risk for progression of disease or acute events, Dr. Willke suggested. He also recommended that researchers identify key comparators, evidence gaps, and likely effects of trial results, and then parse out different types of patients before identifying an intended treatment population.

You Might Also Like
  • Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
  • EULAR 2014: Collaboration Among Rheumatology Groups Expected to Build
  • Tainted Research Repeatedly Re-Used to Assess Drug Effectiveness
Explore This Issue
July 2013
Also By This Author
  • Researchers Propose a Sensitive, Specific Biomarker for Rheumatoid Arthritis

“Payers want trials to reflect clinical practice, and to show which patients will benefit,” said, Christine Fletcher, executive director of biostatistics at Amgen, Inc., who recently set up an HTA biostatistics group at her company. She noted that Germany has a new law requiring trials to investigate which patients get the most benefits from a drug. She gave advice about how statisticians can design drug trials that incorporate payer requirements so that marketed products ultimately receive insurer reimbursement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

To demonstrate a drug is cost effective, it is important to show how a drug performs relative to other interventions in subgroups of patients of interest to insurers, she said. Many studies of relative effectiveness include indirect comparisons, also known as network meta-analyses, which are useful for drugs that have not been studied together in head-to-head clinical trials. Indirect comparisons require a number of assumptions and careful interpretation of results due to potential biases and limitations of the methodology, said Fletcher, who recommended a few ways to add statistical value to indirect comparisons.

These include understanding the existing clinical evidence, assessing clinical and statistical sources of heterogeneity, investigating heterogeneity and variability in treatment effects, and conducting meta-regression analyses to explore important prognostic variables. Key to indirect comparisons is conducting extensive sensitivity analyses that enable the robustness of conclusions to be evaluated, she added.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These tactics make drug products more marketable. “Understand that the traits of the intended treatment population are of the most interest to payers and can aid in strategic development,” Willke said. Such a focus would be good news for rheumatology patients as well.


Deborah Levenson is a medical writer based in College Park, Md.

References

  1. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
  2. Chambers JD, Morris S, Neumann PJ, Buxton MJ. Factors predicting Medicare national coverage: An empirical analysis. Med Care. 2012;50: 249-256.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Drug Updates Tagged With: Drugs, patient care, Research, rheumatology, TreatmentIssue: July 2013

You Might Also Like:
  • Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
  • EULAR 2014: Collaboration Among Rheumatology Groups Expected to Build
  • Tainted Research Repeatedly Re-Used to Assess Drug Effectiveness
  • Clinicians May Have Inaccurate Views of Benefits, Harms of Treatments & Tests

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)